3.61
3.22%
-0.12
Elevation Oncology Inc stock is currently priced at $3.61, with a 24-hour trading volume of 272.25K.
It has seen a -3.22% decreased in the last 24 hours and a -17.77% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.77 pivot point. If it approaches the $3.61 support level, significant changes may occur.
Previous Close:
$3.73
Open:
$3.77
24h Volume:
272.25K
Market Cap:
$197.24M
Revenue:
-
Net Income/Loss:
$-45.70M
P/E Ratio:
-1.0084
EPS:
-3.58
Net Cash Flow:
$-56.18M
1W Performance:
+2.85%
1M Performance:
-17.77%
6M Performance:
+657.93%
1Y Performance:
-5.00%
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
716 371 1125
Address
888 Seventh Avenue, 12th Floor, New York
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-23-21 | Initiated | H.C. Wainwright | Buy |
Elevation Oncology Inc Stock (ELEV) Latest News
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $7.40 Consensus Price Target from Analysts - Defense World
Defense World
Elevation Oncology (NASDAQ:ELEV) Coverage Initiated at Stephens - Defense World
Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of "Buy" from Analysts - MarketBeat
MarketBeat
Elevation Oncology (NASDAQ:ELEV) Research Coverage Started at Stephens - MarketBeat
MarketBeat
Ovarian Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) - openPR
openPR
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference - PR Newswire
PR Newswire
Elevation Oncology Inc Stock (ELEV) Financials Data
Elevation Oncology Inc (ELEV) Net Income 2024
ELEV net income (TTM) was -$45.70 million for the quarter ending December 31, 2023, a +51.93% increase year-over-year.
Elevation Oncology Inc (ELEV) Cash Flow 2024
ELEV recorded a free cash flow (TTM) of -$56.18 million for the quarter ending December 31, 2023, a +34.28% increase year-over-year.
Elevation Oncology Inc (ELEV) Earnings per Share 2024
ELEV earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a +64.06% growth year-over-year.
About Elevation Oncology Inc
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Cap:
|
Volume (24h):